i3 Expands Partnership With Eli Lilly and Company
New Agreement Adds to Existing U.S. Data Management Services Work
ANN ARBOR, MI, September 14, 2010—Pharmaceutical services company i3 announced today that global pharmaceutical firm Eli Lilly and Company (NYSE: LLY) is transferring select activities to support its U.S. clinical trials, including the areas of U.S. medical writing and biostatistical services, to i3 as part of Lilly’s continuing effort to transform its business in order to speed improved outcomes to individual patients. This move marks a significant expansion of the business relationship between the two organizations since Lilly transferred the majority of its U.S. data management operations to i3 in 2008.
This agreement builds on i3’s steady growth in the area of functional service provision (FSP), having composed and deployed successful FSP teams throughout the industry since 1999.
Life science companies have found that partnering with service providers in functional areas, such as information sciences—including data management, medical writing, and biostatistical services—enhances efficiencies, improves quality, and reduces costs. These benefits are critical to companies that need to compete in a dynamic business environment while retaining the capabilities of employees who know their systems and culture.
“i3, with an established presence on the north side of Indianapolis, has proved itself as a partner capable of consistently delivering high-quality work within our agreed-upon performance metrics,” said Aarti Shah, Ph.D., vice president statistics and advanced analytics hub, Eli Lilly and Company.
“The continued expansion of the relationship between Lilly and i3 is another step in the evolution of the successful strategic partnership we share,” said Gregg Dearhammer, group president, i3 Statprobe and i3 Drug Safety. “Over the last four years, our teams have built something truly novel and innovative—a true strategic alliance. This latest addition to our alliance is evidence that emphasis on quality, customer service, efficiency, and ability to deliver are highly valued by our partners like Lilly and critical to their ability to meet their goals.”
About i3 Statprobe
i3 Statprobe provides clinical data services to pharmaceutical, biologic, medical device and diagnostics customers. It is a leader in the development and growth of functional alliances and strategic partnerships, which help enhance efficiencies and reduce costs in clinical trials.
i3 takes a 360-degree view of healthcare to help its global pharmaceutical, biotechnology, and medical device customers bring safe and effective products to market quickly and help demonstrate their value, leading to increased ROI and better patient care. i3’s integrated businesses combine a deep understanding of data and methodologies; therapeutic, scientific, and functional proficiency; and the expertise to help design research that demonstrates a product’s value, and helps achieve market access and assure reimbursement. More information about i3 can be obtained at www.i3global.com.
# # #
(703) 528-7577 (fax)
(703) 801-7955 (cell)
Posted: September 2010
Recommended for you